A review of olanzapine pamoate

Bibliography

• Kane JM. Schizophrenia. N Engl J Med 1996;334:34-41
   PubMed Web of Science ®Google Scholar
• Davis JM. Maintenance therapy and the natural course of schizophrenia. J Clin Psychol 1985;46:18-21
   Google Scholar
• Abott C, Keith S. Antipsychotic treatment and adherence in schizophrenia. In: Haddad P, Lambert T, Lauriello J, editors. Antipsychotic long-acting injections. Oxford University Press; Oxford: 2011
   Google Scholar
• Davis JM, Matalon L, Watanabe MD, Depot antipsychotic drugs. Place in therapy. Drugs 1994;47(5):741-73
   PubMed Web of Science ®Google Scholar
• Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003;64(16):14-17
   PubMedGoogle Scholar
• Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290-9
   PubMed Web of Science ®Google Scholar
• Leucht C, Heres S, Kane JM, Oral versus depot antipsychotic drugs for schizophrenia–a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011;127(1-3):83-92
   PubMed Web of Science ®Google Scholar
• Knegtering H, Oolders H, Ruijsink MA, van der Moolen AE. Depot antipsychotics in the year 2011. Tijdschr Psychiatr 2011;53(2):95-105
   PubMedGoogle Scholar
• Canas F, Moller HJ. Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review. Expert Opin Drug Saf 2010;9(5):683-97
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW. Second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatry Suppl 2009;52:S29-36
   PubMedGoogle Scholar
• Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 2008;68(16):2269-92
   PubMed Web of Science ®Google Scholar
• Siegel SJ. Resurgence of long-acting antipsychotic formulations. Curr Psychiatry Rep 2010;12(4):276-8
   PubMed Web of Science ®Google Scholar
• Chue P. Risperidone long-acting injection. In: Haddad P, Lambert T, Lauriello J, editors. Antipsychotic long-acting injections. Oxford University Press; Oxford: 2011
   Google Scholar
• Bishara D. Once-monthly paliperidone injection for the treatment of schizophrenia. Int J Clin Pract 2010;64(2):216-39
   PubMedGoogle Scholar
• Owen RT. Paliperidone palmitate injection: its efficacy, safety and tolerability in schizophrenia. Drugs Today (Barc) 2010;46(7):463-71
   PubMed Web of Science ®Google Scholar
• Citrome L. Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Neuropsychiatr Dis Treat 2010;6:561-72
   PubMedGoogle Scholar
• Naber D. Olanzapine pamoate for the treatment of schizophrenia. Expert Opin Pharmacother 2011;12(4):627-33
   PubMed Web of Science ®Google Scholar
• Frampton JE. Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia. Drugs 2010;70(17):2289-313
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP. Long-acting injectable antipsychotics: focus on olanzapine pamoate. Neuropsychiatr Dis Treat 2010;6:261-7
   PubMed Web of Science ®Google Scholar
• Di Lorenzo R, Brogli A. Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia. Neuropsychiatr Dis Treat 2010;6:573-81
   PubMed Web of Science ®Google Scholar
• Owen RT. Olanzapine: a review of rapid and long-acting parenteral formulations. Drugs Today (Barc) 2010;46(3):173-81
   PubMed Web of Science ®Google Scholar
• Saesmaa T, Totterman AM. Dissolution studies on ampicillin embonate and amoxycillin embonate. J Pharm Biomed Anal 1990;8(1):61-5
   PubMed Web of Science ®Google Scholar
• Zhao P, Sharir H, Kapur A, Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and beta-arrestin2 with antinociceptive activity. Mol Pharmacol 2010;78(4):560-8
   PubMed Web of Science ®Google Scholar
• Zyprexa® Product Monograph. Eli Lilly Canada, Inc; 3650 Danforth Avenue, Toronto, Ontario, Canada. Date of Revision November 8, 2011
   Google Scholar
• Kapur S, Zipursky RB, Remington G, 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998;155(7):921-8
   PubMed Web of Science ®Google Scholar
• Mamo D, Kapur S, Keshavan M, D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology 2008;33(2):298-304
   PubMed Web of Science ®Google Scholar
• McDonnell DP, Detke HC, Bergstrom RF, Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiatry 2010;10:45
   PubMed Web of Science ®Google Scholar
• Zyprexa® Relprevv™ Full prescribing Information. Lilly LLC, USA; Indianapolis, Indiana, USA: Revised July 52011
   Google Scholar
• Zypadhera® Annex I Summary of Product Characteristics; European Medicines Agency. Date of first authorisation: 19/11/2008. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000890/WC500054429.pdf
   Google Scholar
• Lauriello J, Lambert T, Andersen S, An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008;69(5):790-9
   PubMed Web of Science ®Google Scholar
• Kane JM, Detke HC, Naber D, Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010;167(2):181-9
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhao F, Detke HC, Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia. BMC Psychiatry 2011;11:152
   Google Scholar
• McDonnell DP, Kryzhanovskaya LA, Zhao F, Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine. Hum Psychopharmacol Clin Exp 2011;26:422-33
   PubMed Web of Science ®Google Scholar
• McDonnell DP, Andersen SW, Detke HC,  Long-term safety and tolerability of open-label olanzapine long-acting injection in the treatment of schizophrenia: 190-week interim results. Clinical Medicine Insights: Psychiatry 2011;3:37-47
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00320489?term=olanzapine+pamoate&rank=1 [Accessed 21 February 2012]
   Google Scholar
• Citrome L. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int J Clin Pract 2009;63(1):140-50
   PubMed Web of Science ®Google Scholar
• Akhras KS, Singh J, Gopal S, Comparison of treatment completion rates for olanzapine pamoate and risperidone microspheres. Int J Clin Pract 2009;63(6):962-3
   PubMed Web of Science ®Google Scholar
• Detke HC, Zhao F, Garhyan P, Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching. Int Clin Psychopharmacol 2011;26:35-42
   PubMed Web of Science ®Google Scholar
• McDonnell D, Sorsaburu S, Brunner E, Post-injection delirium/sedation syndrome observed with olanzapine long-acting injection: review of the first 25 events. Eur Neuropsychopharm 2008;18(4):437-8
   Web of Science ®Google Scholar
• Detke HC, McDonnell DP, Brunner E, Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry 2010;10(10):43
   PubMedGoogle Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Curr Med Res Opin 2011;27(4):713-30
   PubMed Web of Science ®Google Scholar
• All Wales Medicines Strategy Group Final Appraisal Report Olanzapine depot (ZypAdhera®) – October 2010. Available from: http://www.wales.nhs.uk/sites3/Documents/371/olanzapine%20depot%20%28ZypAdhera%29%20schizophrenia.pdf [Accessed 21 February 2012]
   Google Scholar
• Scottish Medicines Consortium. Olanzapine 210 mg, 300 mg, 405 mg powder and solvent for prolonged release suspension for injection (ZypAdhera). No. (624/10). Published July 9, 2010 Available from: http://www.scottishmedicines.org.uk/files/olanzapine_ZypAdhera_FINAL_July_2010.pdf [Accessed 21 February 2012]
   Google Scholar
• VA Pharmacy Benefits Management Service, Medical Advisory Panel, and VISN Pharmacist Executives. Olanzapine Pamoate (Zyprexa Relprevv) National Drug Monograph. 2010. Available from: www.pbm.va.gov
   Google Scholar
• Takeuchi H, Suzuki T, Uchida H, Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr Res 2012;134(2-3):219-25
   PubMed Web of Science ®Google Scholar
• Tandon R, Belmaker RH, Gattaz WF, Section of Pharmacopsychiatry, World Psychiatric Association. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008;100(1-3):20-38
   PubMed Web of Science ®Google Scholar
• Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. Schizophr Res 2010;122(1-3):1-23
   PubMed Web of Science ®Google Scholar
• Devadason P. Practical limitations of prescribing olanzapine depot (Relprevv). Australas Psychiatry 2010;18(3):269
   PubMed Web of Science ®Google Scholar
• Taylor DM. Olanzapine pamoate - blockbuster or damp squib? Int J Clin Pract 2009;63(4):540-1
   PubMed Web of Science ®Google Scholar
• Hill AL, Sun B, Karagianis JL, Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia. BMC Psychiatry 2011;15(11):28
   Google Scholar